New York, September 10, 2024 - PRISM MarketView - Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY) and a leading global player in the medical cannabis sector, recently released a new study, “Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS),”. The company’s mission is to connect patients with the latest scientific research in a more convenient way, aiming to treat illness and deliver tailored health advice and guidance with objective data from Tilray’s growing database of over 3 million anonymous medical records.
Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series
We aimed to assess the effectiveness of cannabinoids (Tilray Dried Flower THC18) in the management of chronic pain and other FM-associated symptoms according to patient-reported outcomes, in a series of three FM patients.
Read More
This real-world study based on healthcare providers’ experiences assessed the impact of cannabinoid treatments on individuals diagnosed with fibromyalgia (FM). It evaluated the effects of Dried Flower THC18 from Tilray on chronic pain, sleep disorders, and different symptoms potentially linked to FM. The striking results demonstrate how health outcomes can be impacted by cannabinoids, particularly for pain relief, sleep quality, and overall satisfaction.
The findings showed marked progress in pain management, improved sleep quality, and greatly enhanced health overall for fibromyalgia sufferers, with an average age of 52, under the care of qualified medical cannabis specialists. In addition, subjects reduced dependence on other drugs, implying that cannabinoids might represent an effective and inexpensive option for treating this group.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios, and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities